Evaluation of the exit screening policy among travelers arriving from Asian and pacific nations
- PMID: 38698328
- PMCID: PMC11067274
- DOI: 10.1186/s12879-024-09327-8
Evaluation of the exit screening policy among travelers arriving from Asian and pacific nations
Abstract
Background: The Japanese government has instituted border control measures against COVID-19, including entry and exit screening of people arriving from overseas. We sought to evaluate the effectiveness of the exit screening policy in Japan in reducing the risk of importing COVID-19 cases among travelers from Asian and Pacific countries.
Methods: The study period was stratified based on the timing of exit screening: (i) the control period (the pre-exit screening period from 25 October 2020 to 16 January 2021), (ii) the time period with the Alpha variant from 17 January to 10 April 2021, and (iii) the time period with the Delta variant from 2 May to 2 October 2021. Incidence data in the countries of origin were used to adjust for the risk of infection among travelers. The positivity rate of entry screening in Japan was compared among the three different study periods, adjusting for the risk of infection in the country of origin.
Results: The adjusted relative risk of positivity was greatly reduced and substantially below the value of 1 during the Alpha variant period compared with the control period. Although the relative risks increased when comparing the Delta variant period against control, the estimate remained below 1, except for among travelers from India and Myanmar. The relative risk reduction was greatest in high-income countries, with estimates of 100% and 96% risk reduction during the Alpha and Delta variant periods, respectively, followed by upper-middle-income countries with estimates of 90% and 76%, respectively.
Conclusions: Even in the presence of the Alpha and Delta variants, exit screening clearly reduced the risk of infection among travelers arriving from Asian and Pacific nations. As the testing relies on the country of origin, the effectiveness varied greatly by the socioeconomic income status and epidemiological situation of those countries. Test standardization and quality assurance may be required in low- and middle-income countries.
Keywords: Border control; Effectiveness; Quarantine; Severe acute respiratory syndrome coronavirus 2; Southeast Asia; Statistical estimation; Travel; Western Pacific.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures




Similar articles
-
Assessing exit screening of SARS-CoV-2 in Japan: an analysis of the airport screening data of passengers from the United Kingdom, 2020-2022.BMC Infect Dis. 2024 Sep 12;24(1):962. doi: 10.1186/s12879-024-09894-w. BMC Infect Dis. 2024. PMID: 39267012 Free PMC article.
-
Travel-related control measures to contain the COVID-19 pandemic: a rapid review.Cochrane Database Syst Rev. 2020 Oct 5;10:CD013717. doi: 10.1002/14651858.CD013717. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2021 Mar 25;3:CD013717. doi: 10.1002/14651858.CD013717.pub2. PMID: 33502002 Updated.
-
Epidemiology and Risk of Coronavirus Disease 2019 Among Travelers at Airport and Port Quarantine Stations Across Japan: A Nationwide Descriptive Analysis and an Individually Matched Case-Control Study.Clin Infect Dis. 2022 May 3;74(9):1614-1622. doi: 10.1093/cid/ciab659. Clin Infect Dis. 2022. PMID: 34318872 Free PMC article.
-
International travel-related control measures to contain the COVID-19 pandemic: a rapid review.Cochrane Database Syst Rev. 2021 Mar 25;3(3):CD013717. doi: 10.1002/14651858.CD013717.pub2. Cochrane Database Syst Rev. 2021. PMID: 33763851 Free PMC article.
-
Universal screening for SARS-CoV-2 infection: a rapid review.Cochrane Database Syst Rev. 2020 Sep 15;9(9):CD013718. doi: 10.1002/14651858.CD013718. Cochrane Database Syst Rev. 2020. PMID: 33502003 Free PMC article.
References
-
- Bielecki M, Patel D, Hinkelbein J, Komorowski M, Kester J, Ebrahim S, Rodriguez-Morales AJ, Memish ZA, Schlagenhauf P. Air travel and COVID-19 prevention in the pandemic and peri-pandemic period: a narrative review. Travel Med Infect Dis. 2021;39:101915. doi: 10.1016/j.tmaid.2020.101915. - DOI - PMC - PubMed
-
- Novel Coronavirus Response Headquarters. Resumption of Cross-Border Travel and other measures (28 August 2020). https://www.mofa.go.jp/files/100089889.pdf. Accessed 13 December 2023.
Publication types
MeSH terms
Grants and funding
- 22KJ1852/Japan Society for the Promotion of Science
- 21H03198 and 22K19670/Japan Society for the Promotion of Science
- 20CA2024, 20HA2007, 21HB1002, and 21HA2016, and 23HA2005/Ministry of Health, Labour and Welfare
- JP23fk0108685 and JP23fk0108612/Japan Agency for Medical Research and Development
- JPMEERF20S11804/Environmental Restoration and Conservation Agency
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous